Company Profile
Achieve Life Sciences Stock Price, News & Analysis
- Ticker:
- ACHV
- Exchange:
- NASDAQ
- Sector:
- Life Science Tools
- Location:
- United States
Stock performance
6.55 USD (-1.65%)
Close
Last updated: August 6, 2026
516M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ACHV closed down 1.65% at $6.55. No new same-company headline was identified in the current news window.
Company overview
Nicotine Dependence Company
Achieve Life Sciences develops cytisinicline as a treatment for nicotine dependence and smoking cessation.
Cytisinicline
Cytisinicline is a plant-derived partial agonist of the nicotinic acetylcholine receptor and is intended as a shorter-course alternative to existing prescription therapies.
Phase 3 Evidence
The ORCA-2 and ORCA-3 studies demonstrated higher continuous abstinence rates than placebo, including in participants previously treated with varenicline or bupropion.
Manufacturing Transition
Achieve is transitioning manufacturing after FDA inspection findings at a prior third-party facility affected the current NDA review.
Future catalysts
Near-term attention for Achieve Life Sciences is likely to stay on ORCA-V2. The current setup is really about “If approved, cytisinicline would be the first new FDA-approved smoking cessation therapy in more than two decades, and could also be the first ever for vaping cessation. That is where the next meaningful signal is most likely to come from.
Recent news
- 01
Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality
Source: Achieve Life Sciences
- 02
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
Source: Achieve Life Sciences
- 03
Achieve Life Sciences Joins Russell 2000® Index
Source: Achieve Life Sciences
- 04
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
Source: Achieve Life Sciences
- 05
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Source: Achieve Life Sciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Achieve Life Sciences (ACHV)?
Achieve Life Sciences (ACHV) most recently closed at 6.55 USD, a -1.65% move versus the previous session.
What is the market cap of Achieve Life Sciences (ACHV)?
Achieve Life Sciences currently has a market capitalization of 516M USD on BioPharmSignal.
What does Achieve Life Sciences do?
Nicotine Dependence Company Achieve Life Sciences develops cytisinicline as a treatment for nicotine dependence and smoking cessation. Cytisinicline Cytisinicline is a plant-derived partial agonist of the nicotinic acetylcholine receptor and is intended as a shorter-course alternative to existing prescription therapies. Phase 3 Evidence The ORCA-2 and...
On which exchange is ACHV stock listed?
Achieve Life Sciences (ACHV) is associated with NASDAQ, United States, Life Science Tools.
What is ORCA-2?
Phase 3 Evidence The ORCA-2 and ORCA-3 studies demonstrated higher continuous abstinence rates than placebo, including in participants previously treated with varenicline or bupropion.
Which conditions is Achieve Life Sciences targeting with ORCA-2?
Nicotine Dependence Company Achieve Life Sciences develops cytisinicline as a treatment for nicotine dependence and smoking cessation. Cytisinicline Cytisinicline is a plant-derived partial agonist of the nicotinic acetylcholine receptor and is intended as a shorter-course alternative to existing prescription therapies. Phase 3 Evidence The ORCA-2 and...
How does Achieve Life Sciences describe recent progress with ORCA-2?
Near-term attention for Achieve Life Sciences is likely to stay on ORCA-V2. The current setup is really about “If approved, cytisinicline would be the first new FDA-approved smoking cessation therapy in more than two decades, and could also be the first ever for vaping cessation. That is where the next meaningful signal is most likely to come from.
What is ORCA-3?
Phase 3 Evidence The ORCA-2 and ORCA-3 studies demonstrated higher continuous abstinence rates than placebo, including in participants previously treated with varenicline or bupropion.